Literature DB >> 21491115

[Cardial target-organ damage in diabetes].

W Motz1, W Kerner.   

Abstract

Coronary heart disease and type 2 diabetes mellitus can be considered as a syntropy. Accordingly, cardiologists and diabetologists should organize an interdisciplinary car of the patient with both cardiac disease and diabetes mellitus. Arterial hypertension is frequently present in the diabetic condition and increases further morbidity and mortality rates due to the involvement of the coronary microcirculation. Coronary artery disease is characterized by a rapid progression and a diffuse distribution particularly in the periphery. Consequently in severe diabetic coronary artery disease coronary bypass surgery should be preferred rather than percutaneous coronary stenting, which should be favored in less severe cases. In the antihyperglycemic treatment a reduction in cardiovascular endpoints has only be documented after metformin. Therapy with thiazolidinediones has been terminated due to an increase in coronary morbidity and mortality under rosiglitazone. In as much glucagon-like peptide-I analogues and dipeptidylpeptidase 4 inhibitors will reduce cardiovascular endpoints has to be waited for. Thus an endpoint orientated antihyperglycemic treatment is limited to insulin, metformin and sulfonylureas.

Entities:  

Mesh:

Year:  2011        PMID: 21491115     DOI: 10.1007/s00108-010-2732-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  51 in total

1.  Do insulinotropic glucose-lowering drugs do more harm than good? The hypersecretion hypothesis revisited.

Authors:  I Rustenbeck; S Baltrusch; M Tiedge
Journal:  Diabetologia       Date:  2010-07-01       Impact factor: 10.122

2.  Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.

Authors:  C Lamanna; M Monami; N Marchionni; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2011-03       Impact factor: 6.577

3.  Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial.

Authors:  Akhil Kapur; Roger J Hall; Iqbal S Malik; Ayesha C Qureshi; Jeremy Butts; Mark de Belder; Andreas Baumbach; Gianni Angelini; Adam de Belder; Keith G Oldroyd; Marcus Flather; Michael Roughton; Petros Nihoyannopoulos; Jens Peder Bagger; Kenneth Morgan; Kevin J Beatt
Journal:  J Am Coll Cardiol       Date:  2010-02-02       Impact factor: 24.094

Review 4.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.

Authors:  Dean T Eurich; Finlay A McAlister; David F Blackburn; Sumit R Majumdar; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson
Journal:  BMJ       Date:  2007-08-30

5.  U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461

6.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

7.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

Review 8.  Cardiovascular complications in diabetes: targets and interventions.

Authors:  Alin O Stirban; Diethelm Tschoepe
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

9.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

10.  Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.

Authors:  Ajay D Rao; Nitesh Kuhadiya; Kristi Reynolds; Vivian A Fonseca
Journal:  Diabetes Care       Date:  2008-05-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.